This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
8 Jun 2011

Pfenex and SAFC Ink Strategic Pact

The two companies plan to combine Pfenex’s Reagent Proteins product offerings in the area of vaccine components with SAFC’s expertise and facilities for bioconjugation to support development of conjugate vaccines.

Pfenex Inc. has formed a non-exclusive strategic partnership with SAFC, a unit of the Sigma-Aldrich Corp.

 

Under the agreement, Pfenex will engineer production strains and processes for SAFC’s contract manufacturing customers. The developed processes will then be transferred to SAFC’s fermentation facility in Jerusalem for cGMP production.

 

The two companies also plan to work together to combine Pfenex’s Reagent Proteins product offerings in the area of vaccine components with SAFC’s expertise and facilities for bioconjugation to support development of conjugate vaccines.

 

"Our partnership agreement with SAFC combines a cutting edge e

Related News